Kymera Therapeutics, Inc. Operating Income Loss

• Kymera Therapeutics, Inc. showed a decrease of -33.5% in Operating Income Loss from 2024 to 2025.
• This data is from Kymera Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 7 years of available data (2019 to 2025), Kymera Therapeutics, Inc.'s Operating Income Loss has declined by 727.9%.
• Historical annual values: Fiscal year 2025: -$349.40 million | Fiscal year 2024: -$261.64 million | Fiscal year 2023: -$165.53 million | Fiscal year 2022: -$161.26 million | Fiscal year 2021: -$100.53 million | Fiscal year 2020: -$46.30 million | Fiscal year 2019: -$42.21 million.
• Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: June 23, 2026